Stockholm, Stockholm County, Sweden, September 2025 – Jan Wahlström has been appointed as the new Chief Executive Officer at Devyser. In his new role, he will lead the company’s strategic direction and growth, building on its strong presence in complex DNA diagnostic kits for oncology, hereditary diseases, and transplantation. His focus will be on guiding the next phase of innovation and expanding Devyser’s global reach.
Jan brings with him an extensive background of over two decades in leadership across life sciences and medtech companies. Most recently, he was CEO and President at Alexam AB for 12 years, where he guided the company through a period of consistent growth and operational development. During this time, he also served as CEO of Mabtech, a role he held for three years, strengthening the company’s presence in immunology research tools.
Before that, Jan was CEO and President at Elos Medtech AB, a global medtech solutions provider, for nearly six years. He played a key role in expanding the company’s international operations and building long-term sustainability in the highly competitive medical technology sector. Alongside these roles, he was also CEO, COB, and Owner of Larodan AB, a leading producer of lipid standards for biochemical research.
Earlier in his career, Jan held leadership positions such as Chairman of the Board at Insplorion AB, CEO and President of Biolin Scientific, and CEO and President at Q-Sense. His contributions at Biolin Scientific and Q-Sense were instrumental in advancing nanoscale interface study instruments, making significant inroads into global scientific markets.
Jan began his executive leadership journey as European CEO at Umetrics AB, where he drove regional growth and helped strengthen the company’s reputation in advanced analytics. He also spent over six years at Waters Corporation, serving as Nordic Sales Manager, where he built expertise in sales leadership and customer solutions across the bioprocessing and diagnostics sector.
About Devyser
Devyser is a global specialist in diagnostic kits for complex DNA testing in oncology, hereditary diseases, and transplantation. The company’s products are used to guide targeted cancer therapies, enable rapid prenatal diagnostics, and support post-transplant follow-up. Devyser’s guiding principle is to make advanced testing simple, reproducible, and less prone to error, a commitment that has earned the trust of laboratories in more than 60 countries worldwide.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
